Marina Sardone | Global Head of Patient Advocacy
Alfasigma
I am a dynamic and passionate pharmaceutical leader in the patient advocacy space, currently serving as the Global Head of Patient Advocacy at Alfasigma. With over a decade of experience in the pharmaceutical industry, I am dedicated to improving the lives of patients through advocacy, education, and access to innovative treatments.
My expertise lies in building strategic partnerships with patient organizations to drive patient-centric solutions. Being a strong advocate for patient engagement, including empowerment, I am committed to ensuring that the patient voice is heard and integrated into all aspects of drug development and commercialization.
Prior to my role at Alfasigma, I held various leadership positions in patient advocacy and engagement at leading pharmaceutical companies, with a proven track record of successfully navigating the complex landscape of working with the patient community to bring about positive change for patients and their families.
I also have experience working within patient organizations, consultancy as well as in European institutions. I hold a degree in International Relations, Political Sciences.
With specific interest in the orphan drug and rare disease space, I am dedicated to driving collaboration and innovation in the field of rare diseases to ultimately improve outcomes and quality of life for those affected by these conditions.
Appearances:
Day 1- World Orphan Drug Congress USA 2025 @ 14:00
Roundtable 1: From discovery to access: Harnessing patient engagement and patient experience data throughout the Rare Disease drug development journey & beyond
Every stakeholder in the rare disease ecosystem – from researchers, developers, regulators, and policymakers to healthcare professionals and patient organisations – aims to improve the health outcomes for patients. Yet, the voices, lived experiences and priorities of the rare disease patient community (including families, caregivers and loved ones) often go unheard.
At the same time, patient engagement (PE) and patient experience data (PED) are emerging as key enablers in research and healthcare to deliver evidence-based patient unmet needs, health outcomes and impact. Optimizing patient health outcomes through the integration of PE & PED across research and healthcare systems should now be a priority for all the stakeholders in the healthcare ecosystem.
How can we bridge this gap and ensure PED, integrated with PE, becomes a driving force in clinical development and healthcare decision-making in the rare disease space - addressing evidence-based patients’ unmet needs and priorities?
Join us for an engaging and open conversation on the role of PE and PED in rare diseases and share your insights and experiences on the value patient-driven data can bring patients, society and businesses.
Sponsored by Alfasigma.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events